NHS England Drugs of Low Clinical Priority

Pin It

NHS England have identified 18 medicines/items of low clinical value. These are for ineffective, over-priced or low value treatments and are a focus in our Medicines Optimisation LES (MOLES).

Below are the resources to support practices when reviewing them which includes  prescribing policy statements, service restriction policies and switching guidance for each item.

pdf Complementary and Alternative Therapies Service Restriction Policy Oct 2016 (126 KB)

Co-proxamol MSEMOC May 21

pdf Dosulepin August 2017 (325 KB)

Doxazosin MR August 2017 

Erectile dysfunction - Tadalafil January 2019

Fentanyl Immediate release products Oct 20

Glucosamine MSEMOC Jul21

pdf Gluten free food January 2016 (274 KB)

Lidocaine MSEMOC policy statement May 21

document Lidocaine weaning patient letter (19 KB)

Liothyronine MSEMOC position statement Nov 20

pdf Lutein and antioxidants August 2017 (160 KB)

Omega 3 fatty acids MSEMOC Jul 21

Oxycodone & Naloxone combination product (Targinact) MSEMOC position statement Oct 20

Perindopril Arginine August 2017

Rubefacients June 2016

pdf (82 KB) Tramadol & paracetamol combination product (Tramacet®) MSEMOC position statement Oct 20

pdf Travel Vaccines April 2017 (358 KB)

pdf Patient FAQ NHS England low clinical priority Jan 2018 Final (324 KB)